http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2729936-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e5a31d29d88179e4188657a305be08f3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-025 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P33-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P21-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F5-025 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F5-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-69 |
| filingDate | 2011-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6afa6154dac8a7129a6aeaff1bc3bfa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a2d595b57f97d3caac23963c8088dc6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_aa092f53136d951a368d67161c3555bf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5149910e1660fe14d0a65fbf9a219f1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0cc5a09964492601e031d879da6809e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d263190cfeb1233467622496f1bf4f0 |
| publicationDate | 2019-11-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2729936-T3 |
| titleOfInvention | Arginase inhibitors and their therapeutic applications |
| abstract | A compound according to Formula II, ** Formula ** wherein R6 is selected from the group consisting of ORa and NRbRc; Ra is selected from the group consisting of hydrogen, (C1-C6) straight or branched chain alkyl, (C3-C8) cycloalkyl, (C3-C14) aryl, (C3-C14) heterocycloalkyl- (C1-C6) alkylene- , (C3-C14) heteroaryl- (C1-C6) alkylene- and (C3-C14) aryl (C1-C6) alkylene-; Rb and Rc are each independently selected from the group consisting of H, -OH, (C1-C6) linear or branched alkyl, -S (O) 2- (C1-C6) alkyl, (C3-C14) aryl-S (O) 2-, (C3-C14) heterocycloalkyl- (C1-C6) alkylene- and (C3-C14) hetero aryl- (C1-C6) alkylene-; R7 is selected from the group consisting of H, (C1-C6) linear or branched alkyl, (C3-C14) aryl (C1-C6) alkylene-, (C3-C14) heteroaryl- (C1-C6) alkylene-, ( C3-C14) heterocycloalkyl- (C1-C6) alkylene- and (C1-C6) alkyl-C (O) -; X is selected from the group consisting of (C3-C14) -cycloalkylene and (C3-C14) heterocycloalkylene, Y is selected from the group consisting of H, (C1-C14) alkyl, -NR'R ", hydroxy (C1- C6) alkylene, (C3-C14) -cycloalkyl, (C3-C14) -cycloalkyl- (C1-C6) alkylene, (C3-C14) aryl, (C3-C14) aryl- (C1-C6) alkylene, (C3 - C14) heterocycloalkyl, (C3-C14) heterocycloalkyl- (C1-C6) alkylene, (C3-C14) heteroaryl, (C3-C14) heteroaryl- (C1-C6) alkylene, (C3-C14) heteroaryl- (C3- C6) heterocycloalkylene-, (C3-C14) aryl- (C3-C14) heterocycloalkylene-, (C3-C14) -aryl- (C1-C6) alkylene- (C3-C14) heterocycloalkylene-, (C3-C14) heteroaryl- (C1-C6) alkylene- (C3-C14) heterocycloalkylene- and (C3-C14) heterocycloalkyl- (C1-C6) alkylene- (C3-C14) heterocycloalkylene-; M is selected from the group consisting of a bond, - ( C1-C6) alkylene-, -O-, -C (O) -, -C (S) -, - C (O) NH-, -C (S) NH-, -S-, -S (O) -, -S (O) 2- and -NR'-; R8 and R9 are independently selected from hydrogen, (C1-C6) linear or branched alkyl, (C3-C8) cycloalkyl, (C3-C14) aryl and C (O) -R ', or R8 and R9 together with the boron atom to which they are attached form a 5 or 6-membered ring that is completely saturated, or partially saturated and optionally contains 1 -3 additional members of the heteroatom ring selected from O, S and N, wherein the ring is optionally fused with a heterocyclic or aromatic cycloalkyl ring; D is butylene; R 'and R "are independently selected from the group consisting of H, (C1-C8) alkyl, -C (O) - (C1-C8) alkylene, (C3-C6) optionally substituted aryl, (C3-C14) aryl (C1-C6) optionally substituted alkylene, (C1-C6) optionally substituted aminoalkyl, (C3-C6) optionally substituted cycloalkyl, (C3-C14) optionally substituted heterocycloalkyl, (C3-C14) optionally substituted heteroaryl; and wherein any alkyl, alkylene, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted with one or more members selected from the group consisting of halogen, oxo, -COOH, -CN, -NO2, -OH, - NRdRe, -NRgS (O) 2Rh, (C1-C6) alkyl, (C1-C6) haloalkyl, (C1-C6) haloalkoxy, (C1-C6) alkoxy, (C3-C14) aryl, (C3-C14) heterocaryl, (C3-C14) heterocycloalkyl , (C3-C14) heteroaryl- (C1-C6) alkylene and (C3-C14) aryloxy; wherein Rd, Re, Rg and Rh are each independently selected from the group consisting of H, (C1-C6) linear alkyl or branched, (C3-C14) aryl (C1-C6) alkyl optionally substituted leno-, (C3-C14) aryl (C1-C6) hydroxyalkyl, (C1-C6) aminoalkyl, H2N (C1-C6) alkylene-, optionally substituted, (C3-C6) optionally substituted cycloalkyl, (C3-C14 ) optionally substituted heterocycloalkyl, (C3-C14) optionally substituted heteroaryl, (C3-C14) aryl- (C1-C6) optionally substituted alkylene and NR'R "C (O) -, or a salt, stereoisomer or tautomer thereof pharmaceutically acceptable. |
| priorityDate | 2010-04-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1712.